NanosonicsNNCSF 90 Pretax Margin % is 10.39% as of Dec. 2025, which is 6% below its 10-year median of 11.00. GuruFocus rates NNCSF with a GF Score™ of 90/100 and a GF Value™ of $3.57 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 817 Medical Devices & Instruments companies, Nanosonics ranks better than 69.16% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Nanosonics's Pre-Tax Income for the
six
months ended in Dec. 2025 was $7.1 Mil. Nanosonics's Revenue for the
six
months ended in Dec. 2025 was $67.9 Mil. Therefore, Nanosonics's pretax margin for the quarter that ended in Dec. 2025 was 10.39%.
The historical rank and industry rank for Nanosonics's Pretax Margin % or its related term are showing as below:
NNCSF'
s Pretax Margin % Range Over the Past 10 Years
Min: 0.32 Med: 11 Max: 20.52
Current: 10.6
NNCSF's Pretax Margin % is ranked better than 69.16% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.43
vs NNCSF: 10.60
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Nanosonics Pretax Margin % Related Terms
Nanosonics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Nanosonics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNCSF vs ISRG, BDX, MDLN: Pretax Margin % Comparison
For the Medical Instruments & Supplies subindustry, Nanosonics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosonics Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Nanosonics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanosonics (NNCSF) has a Pretax Margin % of 10.39% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Nanosonics and its competitors. This is near median its historical median of 11.00. Over the past decade, Nanosonics' Pretax Margin % has ranged from 0.32 to 20.52. According to the industry distribution chart, Nanosonics ranks #252 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 30.8%.
Is Nanosonics' Pretax Margin % too high?
Nanosonics' current Pretax Margin % of 10.39% is near median its 10-year median of 11.00. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 20.52. The Medical Devices & Instruments industry median Pretax Margin % is 2.43. Nanosonics' value of 10.39% is 327.6% above this industry median. Based on the distribution chart, Nanosonics ranks #252 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nanosonics has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanosonics' Pretax Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nanosonics ranks #252 out of 817 companies for Pretax Margin %. This puts Nanosonics in the upper half of its industry. The industry median Pretax Margin % is 2.43. Nanosonics' value of 10.39% is 327.6% above this benchmark. Historically, Nanosonics' own Pretax Margin % has ranged from 0.32 to 20.52 over the past decade. While the company's 10-year median is 11.00 vs. the industry median of 2.43, Nanosonics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.43, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanosonics's current Pretax Margin % of 10.39% is 327.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Nanosonics and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanosonics's current Pretax Margin % is 10.39%, which is near median its own 10-year median of 11.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosonics stock overvalued right now?
Based on GuruFocus' analysis, Nanosonics (NNCSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.57, compared to a current price of $2.55 — trading 28.6% below its estimated fair value. The current Pretax Margin % is 10.39%, which is near median its 10-year median of 11.00 and 327.6% above the Medical Devices & Instruments industry median of 2.43. Nanosonics' overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Nanosonics (NNCSF), the current Pretax Margin % is 10.39% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanosonics (NNCSF) Overvalued in 2026?
Based on GuruFocus' analysis, Nanosonics stock appears to be undervalued.
The current stock price of $2.55 is trading 28.6% below its estimated GF Value™ of $3.57.
GuruFocus considers Nanosonics to be Modestly Undervalued.
Key valuation signals for NNCSF:
Pretax Margin %: 10.39% (near median its 10-year median of 11.00)
GF Value™: $3.57 vs. price of $2.55 (28.6% below fair value)
Industry Position: 327.6% above the Medical Devices & Instruments median (#252 of 817)
No single metric tells the full story. See the NNCSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics' revenue consists of capital sales of Trophon units, ongoing consumables sales, and service revenue. By December 2025, there were 38,000 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, over 50% in the US to single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
90GF Score
Get the complete analysis for NNCSF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNCSF has been successfully added to your 
